Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will
Commercial Momentum Builds Following CPT Code Implementation
Revenue Recognition on Eight Purchased Units Shifted to Q3 Due to Financing Approval Timing
CMS Proposed 26% Increase in Hospital-Based Delivery Code,
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today
Proprietary cloud-based software and add-on solution designed to provide current and future SRT-100 users with enhanced workflow, operating intelligence and clinical utility
Creates a scalable, recurring-revenue
New financing program provides a "one-stop" pathway for practices to acquire systems through outright purchase or several attractive leasing alternatives
Supports improved conversion of late-stage prospects as
2026 CMS Physician Fee Schedule Final Rule provides a 300% per-fraction increase to delivery code that became effective January 1, 2026
Company enters 2026 with reimbursement certainty and strategic visibility,
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions,
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today
New responsibilities recognize Mr. Sardano's significant accomplishments in securing CPT® codes for office-based SRT and the growing commercial opportunity the Company now faces
Sensus Healthcare, Inc.
Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence
Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in
Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer
Revenues of $6.9 million
Shipped 16 SRT systems including three
